Furthermore, because fructose elicits GLP-1 secretion without simultaneous release of glucagonotropic GIP, the pathways underlying fructose-stimulated GLP-1 release might be useful targets for drug development aiming at stimulating GLP-1 secretion for the treatment of type 2 diabetes and obesity. Here, GIP is linked to type 2 diabetes mellitus.